TapewireFind a company

person · Reporting owner

Schneyer Mark C.

Disclosed activity across 1 company

Tapewire entity
25550
SEC CIK
0001899977

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACADIA PHARMACEUTICALS INCACAD · Entity 3913EVP, CHIEF FINANCIAL OFFICERAugust 05, 2026August 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date August 05, 2026 · Filed August 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect73,677 Reported balance After 2026-08-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-08-05 · Exercise / conversion · Acquired 5,849 · Balance 73,677

F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

Common StockSEC Table I · non-derivativeDirect67,828 Reported balance After 2026-08-05 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-08-05 · Sale · Disposed 5,849 · Balance 67,828

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Common StockSEC Table I · non-derivativeDirect82,120 Reported balance After 2026-08-06 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-08-06 · Exercise / conversion · Acquired 14,292 · Balance 82,120

Common StockSEC Table I · non-derivativeDirect77,120 Reported balance After 2026-08-06 transaction · row 4 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 4 · 2026-08-06 · Sale · Disposed 5,000 · Balance 77,120

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Common StockSEC Table I · non-derivativeDirect67,828 Reported balance After 2026-08-06 transaction · row 5 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 5 · 2026-08-06 · Sale · Disposed 9,292 · Balance 67,828

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24Direct74,715 Reported balance After 2026-08-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-08-05 · Exercise / conversion · Disposed 5,849 · Balance 74,715

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.84 · Expires 2034-03-24Direct60,423 Reported balance After 2026-08-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-08-06 · Exercise / conversion · Disposed 14,292 · Balance 60,423

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

F2: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 06, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionStock Option (Right to Buy) · Derivative 14,292 $0.00 Strike: $17.84 $0.00
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · derivative · entry 7

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,423

Underlying: Common Stock · 14,292 shares

Expires 2034-03-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
August 06, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 9,292 $29.34 $272,604.05
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,828

F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Read SEC document
August 06, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,000 $29.00 $145,000.00
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,120

F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

Read SEC document
August 06, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 14,292 $17.84 $254,969.28
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 05, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionStock Option (Right to Buy) · Derivative 5,849 $0.00 Strike: $17.84 $0.00
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · derivative · entry 6

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,715

Underlying: Common Stock · 5,849 shares

Expires 2034-03-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
August 05, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 5,849 $29.00 $169,637.96
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,828

F2 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
August 05, 2026 Filed Aug 7, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,849 $17.84 $104,346.16
Disclosure

SEC source: 0001899977-26-000008 · form4-08072026_060801.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,677

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.

Read SEC document
May 04, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,506 $21.79 $76,395.74
Disclosure

SEC source: 0001899977-26-000007 · form4-05052026_060501.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,145

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.7932, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 01, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 6,815 $0.00 $0.00
Disclosure

SEC source: 0001899977-26-000007 · form4-05052026_060501.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,815

Underlying: Common Stock · 6,815 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2026 Filed May 5, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 6,815 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-26-000007 · form4-05052026_060501.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,651

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 07, 2026 Filed Apr 7, 2026 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,709 $22.20 $60,139.80
Disclosure

SEC source: 0001899977-26-000005 · form4-04072026_110411.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,836

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
April 05, 2026 Filed Apr 7, 2026 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,276 $0.00 $0.00
Disclosure

SEC source: 0001899977-26-000005 · form4-04072026_110411.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,276 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2026 Filed Apr 7, 2026 23:57 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,276 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-26-000005 · form4-04072026_110411.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 37 $21.72 $803.54
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,269

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 26, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,171 $21.65 $68,652.15
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,306

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 6,178 $0.00 $0.00
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · derivative · entry 7

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,358

Underlying: Common Stock · 6,178 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 6,178 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 4,177 $21.47 $89,680.19
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,299

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 8,138 $0.00 $0.00
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · derivative · entry 6

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,414

Underlying: Common Stock · 8,138 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 8,138 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-26-000003 · form4-03262026_080301.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 26,382 $0.00 $0.00
Disclosure

SEC source: 0001899977-26-000002 · form4-03102026_060310.xml · derivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,382

Underlying: Common Stock · 26,382 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027.

Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Option (Right to Buy) · Derivative 90,691 $0.00 Strike: $22.16 $0.00
Disclosure

SEC source: 0001899977-26-000002 · form4-03102026_060310.xml · derivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,691

Underlying: Common Stock · 90,691 shares

Expires 2036-03-05

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 10,262 $23.69 $243,113.96
Disclosure

SEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,338

F3 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 9,913 $0.00 $0.00
Disclosure

SEC source: 0001899977-25-000006 · form4-11192025_061103.xml · derivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 9,913 $0.00 $0.00
Disclosure

SEC source: 0001899977-25-000006 · form4-11192025_061103.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 9,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 9,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001899977-25-000006 · form4-11192025_061103.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 327 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan.

Read SEC document
September 15, 2025 Filed Sep 16, 2025 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,498 $23.65 $82,727.70
Disclosure

SEC source: 0001899977-25-000004 · form4-09162025_100915.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,447

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
September 12, 2025 Filed Sep 16, 2025 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantCommon Stock 6,815 $0.00 $0.00
Disclosure

SEC source: 0001899977-25-000004 · form4-09162025_100915.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,945

F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024, the performance stock units have vested at 75% of target.

Read SEC document
August 18, 2025 Filed Aug 19, 2025 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 22,000 $25.18 $554,023.80
Disclosure

SEC source: 0001415889-25-022359 · form4-08192025_060803.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,130

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
May 16, 2025 Filed May 20, 2025 00:50 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,000 $25.00 $50,000.00
Disclosure

SEC source: 0001415889-25-013741 · form4-05202025_120539.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,130

F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024.

F2 · balance_after: Includes 1,357 shares of the Issuer's common stock acquired by the Reporting Person on May 15, 2025 pursuant to an employee stock purchase plan.

Read SEC document
May 02, 2025 Filed May 2, 2025 23:59 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,498 $14.60 $51,070.80
Disclosure

SEC source: 0001415889-25-011872 · form4-05022025_110505.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,773

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
May 01, 2025 Filed May 2, 2025 23:59 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 6,815 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-011872 · form4-05022025_110505.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,630

Underlying: Common Stock · 6,815 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2025 Filed May 2, 2025 23:59 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 6,815 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-011872 · form4-05022025_110505.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,271

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
April 08, 2025 Filed Apr 8, 2025 23:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,708 $14.82 $40,132.56
Disclosure

SEC source: 0001415889-25-010424 · form4-04082025_110409.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,456

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
April 05, 2025 Filed Apr 8, 2025 23:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 5,275 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-010424 · form4-04082025_110409.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,276

Underlying: Common Stock · 5,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2025 Filed Apr 8, 2025 23:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 5,275 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-010424 · form4-04082025_110409.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,164

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 26, 2025 Filed Mar 27, 2025 00:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 3,171 $17.05 $54,065.55
Disclosure

SEC source: 0001415889-25-009074 · form4-03272025_120306.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,889

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
March 25, 2025 Filed Mar 27, 2025 00:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 6,178 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,536

Underlying: Common Stock · 6,178 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Read SEC document
March 25, 2025 Filed Mar 27, 2025 00:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 6,178 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-009074 · form4-03272025_120306.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 24, 2025 Filed Mar 27, 2025 00:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 32,552 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,552

Underlying: Common Stock · 32,552 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Read SEC document
March 24, 2025 Filed Mar 27, 2025 00:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Option (Right to Buy) · Derivative 110,761 $0.00 Strike: $17.23 $0.00
Disclosure

SEC source: 0001415889-25-009074 · form4-03272025_120306.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,761

Underlying: Common Stock · 110,761 shares

Expires 2035-03-23

F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 23:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 773 $19.96 $15,429.08
Disclosure

SEC source: 0001415889-25-005574 · form4-02252025_110254.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,882

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Read SEC document
February 23, 2025 Filed Feb 25, 2025 23:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,353 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-005574 · form4-02252025_110254.xml · derivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2025 Filed Feb 25, 2025 23:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-005574 · form4-02252025_110254.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 19, 2024 Filed Nov 20, 2024 01:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 10,259 $16.81 $172,453.79
Disclosure

SEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 3

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,302

F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.768 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 9,913 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-027292 · form4-11202024_011103.xml · derivative · entry 5

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,913

Underlying: Common Stock · 9,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 9,913 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-027292 · form4-11202024_011103.xml · derivative · entry 4

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,913

Underlying: Common Stock · 9,913 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 9,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 2

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,561

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 17, 2024 Filed Nov 20, 2024 01:40 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 9,913 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-027292 · form4-11202024_011103.xml · nonDerivative · entry 1

Schneyer Mark C. · CIK 0001899977 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.